Summary & Overview
HCPCS J7183: Von Willebrand Factor Complex (Wilate), 1 IU vwf:rco
HCPCS Level II code J7183 denotes the injection of von Willebrand factor complex (human), Wilate, billed per 1 international unit of vwf:rco. This code is used to capture administration of a concentrated biologic replacement therapy for patients with von Willebrand disease and certain bleeding diatheses. Nationally, accurate coding for J7183 matters for clinical documentation, inventory management of high-cost biologics, and appropriate payer reimbursement for infusion services.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical use of Wilate, expected sites of service such as infusion centers and hospital outpatient departments, and the role of J7183 in claims for therapeutic biologic injections. The publication outlines typical billing considerations, common modifiers used with injectable biologics (input provided separately), and where to find policy or coverage variations by payer.
This summary provides benchmarks and policy-relevant guidance at a national level: how J7183 is recorded on the service line, implications for drug coding versus administration charges, and important clinical context for claims reviewers and revenue cycle staff. Data not available in the input is noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J7183 represents an injection of von Willebrand factor complex (human), specifically Wilate, billed per 1 international unit of vwf:rco. The service type is a therapeutic biologic infusion/injection, administered to replace or supplement von Willebrand factor in patients with von Willebrand disease or related bleeding disorders. The typical site of service is an infusion center, hospital outpatient department, or other clinical setting capable of administering injectable biologic therapies.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual diagnosed with von Willebrand disease (VWD) presenting for replacement therapy with a von Willebrand factor concentrate product, specifically Wilate. The patient may be scheduled for elective infusion before a surgical, dental, or invasive procedure to prevent bleeding, or may present for treatment of active bleeding such as mucosal hemorrhage or traumatic bleeding. The clinical workflow begins with hematology or a specialized infusion clinic confirming the VWD subtype and factor level, ordering J7183 dosed in international units (vWF:RCo), obtaining baseline vital signs and venous access, preparing weight-based dosing, and administering intravenous infusion under nursing supervision. Post-infusion monitoring includes assessment for hemostasis, allergy or anaphylaxis, thrombotic signs, and documentation of lot number and units infused. Typical sites of service include hospital outpatient infusion centers, ambulatory infusion suites, specialty hematology clinics, and inpatient hospital settings when used for acute bleeding or perioperative management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no special circumstances apply and standard billing is appropriate |